miRNA Nucleic Acid Probes for Non-Invasive Pancreatic Cancer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting early pancreatic cancer or pancreatic cancer precursor lesions are inadequate due to low sensitivity and specificity of existing tumor markers, leading to false positives and negatives, and the invasiveness of tissue sampling, which complicates early detection and treatment.
Innovation Solution
A kit and device utilizing nucleic acids specifically binding to miRNAs such as miR-6784-5p, miR-1181, and others to detect early pancreatic cancer or pancreatic cancer precursor lesions from blood samples, providing a non-invasive method for accurate identification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If tissue sampling is used for detection, then detection accuracy may be improved, but invasiveness increases and patient comfort deteriorates
Solution Approach 1:
The patent uses miRNA molecules in blood as intermediary markers that indirectly indicate the presence of pancreatic cancer or precursor lesions. Instead of directly sampling pancreatic tissue, the detection system analyzes circulating miRNAs that are released from tumor cells into the bloodstream, serving as a non-invasive proxy for tissue-based detection.
Solution Approach 2:
The patent replaces the mechanical tissue sampling process (biopsy) with a biochemical analysis of blood samples. The detection system uses nucleic acid hybridization techniques to identify specific miRNA sequences in circulating blood, substituting the physical invasion of tissue sampling with a minimally invasive blood draw and molecular analysis.
2Ease of operation
If conventional tumor markers are used, then detection can be performed, but sensitivity and specificity are low leading to false results
Solution Approach 1:
The patent changes the detection parameter from conventional protein-based tumor markers (like CA19-9) to nucleic acid-based miRNA markers. This parameter change enables more specific detection because miRNA sequences can be uniquely identified through hybridization with complementary nucleic acid probes, providing higher sensitivity and specificity compared to protein marker assays.
Solution Approach 2:
The detection system uses a composite approach combining multiple miRNA markers (including hsa-miR-1225-3p, hsa-miR-3196, hsa-miR-638, and others) to improve detection accuracy. By analyzing a panel of multiple miRNA markers rather than a single marker, the system achieves higher sensitivity and specificity through the combined diagnostic information from multiple molecular indicators.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution significantly enhances the detection sensitivity and specificity for early pancreatic cancer and precursor lesions, reducing false positives and negatives, and allows for early intervention through non-invasive blood-based testing.
Implementation Method 1
a nucleic acid capable of specifically binding to a particular miRNA
Data Source
AI summary
This application provides a kit or a device for the detection of early pancreatic cancer or a pancreatic cancer precursor lesion, comprising a nucleic acid(s) capable of specifically binding to a miRNA(s) in a sample from a subject, and a method for detecting early pancreatic cancer or a pancreatic cancer precursor lesion, comprising measuring an expression level(s) of the miRNA(s) in vitro.